Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
05/26/17 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference 05/09/17Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132) 05/05/17
EventsBank of America Merrill Lynch 2017 Healthcare Conference05/16/17 9:20 a.m. PTView event1st Quarter 2017 Financial Results04/27/17 4:30 p.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|